Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

• Published in: BMC pulmonary medicine Vol. 21; no. 1; pp. 1 - 13
• Main Authors: Schmid, Ulrike, Weber, Benjamin, Sarr, Celine, Freiwald, Matthias
• Format: Journal Article
• Language: English
• Published: London BioMed Central 21.07.2021; BioMed Central Ltd; BMC
• Subjects: Clinical trials; Critical Care Medicine; Diarrhea; Dose-response relationship (Biochemistry); Drug dosages; Drug therapy; Enzymes; Exposure–safety relationship; Fibrosis; Idiopathic pulmonary fibrosis; Intensive; Internal Medicine; Labeling; Laboratories; Liver; Liver enzyme elevation; Lung diseases; Lung diseases, Interstitial; Medicine; Medicine & Public Health; Nintedanib; Patients; Pharmacokinetics; Pharmacology, Experimental; Phenotypes; Plasma; Pneumology/Respiratory System; Progressive fibrosing ILDs; Pulmonary fibrosis; Pulmonology; Scleroderma; Scleroderma (Disease); Sex differences; Systemic scleroderma; Systemic sclerosis; Systemic sclerosis-associated interstitial lung disease; Transaminase; Germany; United States > US; Nintedanib; Exposure–safety relationship; Progressive fibrosing ILDs; Idiopathic pulmonary fibrosis; Liver enzyme elevation; Systemic sclerosis-associated interstitial lung disease
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-021-01598-0

Background Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib is 150 mg twice daily (BID). Methods Data from Phase II and III trials in IPF and Phase III trials in SSc-ILD and progressive fibrosing ILDs other than IPF were analyzed to investigate the relationship between nintedanib plasma concentrations (exposure) and safety (liver enzyme elevations [defined as transaminase elevations equal or greater than 3 times the upper limit of normal] and diarrhea). Results Using data from 1403 subjects with IPF treated with 50–150 mg nintedanib BID, a parametric time-to-first-event model for liver enzyme elevations was established. Besides exposure, gender was a significant covariate, with a three–fourfold higher exposure-adjusted risk in females than males. Subsequent analysis of combined data from IPF, SSc-ILD (n = 576) and progressive fibrosing ILD (n = 663) studies suggested a consistent exposure–liver enzyme elevation relationship across studies. No exposure–diarrhea relationship was found using data from the various fibrosing ILDs, but diarrhea risk was dependent on dose administered. Conclusions The positive correlation between exposure and risk of liver enzyme elevations was consistent across nintedanib studies in IPF, SSc-ILD and progressing fibrosing ILDs other than IPF. The effect size does not warrant a priori dose adjustment in patients with altered plasma exposure (excluding hepatic impairment patients, where there are specific labelling recommendations). For diarrhea, dose administered was a better predictor than exposure.